64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
Titel:
64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
Auteur:
Sacco, J.J. Carvajal, R. Butler, M.O. Shoushtari, A.N. Hassel, J.C. Ikeguchi, A. Hernandez-Aya, L. Nathan, P. Hamid, O. Rodriguez, J.M. Piulats Rioth, M. Johnson, D.B. Luke, J.J. Espinosa, E. Leyvraz, S. Goodall, H.M. Holland, C. Abdullah, S. Sato, T.